2022 WCLC Highlights

CME

Independent Conference Coverage of the IASLC 2022 World Conference on Lung Cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 25, 2022

Expiration: October 24, 2023

Wade T. Iams
Wade T. Iams, MD, MSCI
Heather Wakelee
Heather Wakelee, MD

Activity

Progress
1
Course Completed

References

  1. Altorki NK, Wang X, Kozono D, et al. Lobar or sub-lobar resection for peripheral clinical stage IA = 2 cm non-small cell lung cancer (NSCLC): results from an international randomized phase III trial (CALGB 140503 Alliance). Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract PL03.06.
  2. Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399:1607-1617.
  3. Provencio M, Serna R, Nadal E, et al. Progression free survival and overall survival in NADIM II study. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract PL03.12.
  4. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.
  5. Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Presented at: 2021 American Society of Clinical Oncology annual meeting; June 4-8, 2021. Abstract 8500.
  6. Felip E, Wakelee H, Altoriki NK, et al. IMpower010: Overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract PL03.09.
  7. Zhou C, Thakur MD, Srivastava MK, et al. IMpower010: Biomarkers of disease-free survival (DFS) in a phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract 20.
  8. Rodriguez-Abreu D, Wu Y, Boyer M, et al. Pooled analysis of outcomes with second-course pembrolizumab across 5 phase 3 studies of non-small-cell lung cancer. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract OA15.06.
  9. Reckamp KL, Redman MW, Dragnev KH, et al. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. Presented at: 2022 American Society of Clinical Oncology annual meeting; June 3-7, 2022. Abstract 9004.
  10. Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017;8:28725-28735.
  11. Meric-Bernstam F, Spira AI, Lisberg AE, et al. TROPION-PanTumor01: dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC). Presented at: 2021 American Society of Clinical Oncology annual meeting; June 4-8, 2021. Abstract 9058.
  12. Levy B, Paz-Ares L, Rixe O, et al. TROPION-Lung02: Initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract MA13.07.
  13. Besse B, Awad MM, Forde PM, et al. HUDSON: An open-label, multi-drug, biomarker-directed phase 2 study in nsclc patients who progressed on anti-PD-(L)1 therapy. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract OA15.05.
  14. Li BT, Falchook G, Durm GA, et al. CodeBreaK 100/101: First report of safety/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract OA03.06.
  15. Falchook G, Li BT, Marrone KA, et al. Sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract OA03.03.
  16. Griffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27:1526-1537.
  17. Owonikoko TK, Champiat S, Johnson ML, et al. Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). Presented at: 2021 American Society of Clinical Oncology annual meeting; June 4-8, 2021. Abstract 8510.
  18. Borghaei H, Paz-Ares L, Johnson ML, et al. Phase 1 updated exploration and first expansion data for DLL3-targeted T-cell engager tarlatamab in small cell lung cancer. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract OA12.05.
  19. Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346-360.
  20. Norris RP, Dew R, Todd A, et al. Socio-economic inequalities in NSCLC treatment during the era of tumour biomarker guided therapy: A population-based study. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract OA01.05.
  21. Murray RL, Brain K, Britton J, et al. Personalised smoking cessation support in a lung cancer screening programme: the Yorkshire Enhanced Stop Smoking Study (YESS). Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022. Abstract PL03.03.